Novo Nordisk and Viatris have agreed to resolve a patent dispute over Novo's blockbuster weight-loss drugs Ozempic and Wegovy ...

State workers’ access to weight loss drugs has put House Speaker Tim Moore at odds with State Treasurer Dale Folwell, who ran ...

Novo Nordisk (NVO) and Viatris (VTRS) have reportedly reached an agreement in their dispute over U.S. patents protecting Novo ...

The company is expected to present critical results from a trial of its CagriSema weight-loss injection in the fourth quarter ...

In a major milestone the obesity rate dropped by roughly 2% between 2020 and 2023 according to the national health and ...

A new study shows semaglutide medications, such as Ozempic and Wegovy, may be effective in treating hidradenitis suppurativa ...

Originally approved to help with excess weight and obesity, the injectable Wegovy and its sibling-product Ozempic, which is ...

A new trial reveals that weekly injections of the weight-loss drug Wegovy (semaglutide) lowered the risk of death from COVID-19 by about a third and reduced overall mortality by 19%.

Novo Nordisk says Massachusetts plays a key role in its bid to expand beyond its historic focus as a diabetes and obesity ...

With a new patent settlement, generic partners Mylan and Natco have cleared one hurdle to a potential U.S. launch of their ...

Originally approved to help with excess weight and obesity, the injectable Wegovy and its sibling-product Ozempic, which is for type 2 diabetes, have become synonymous with weight loss fads. Here’s ...

Medicare covers Wegovy as a treatment to reduce the risk of serious cardiovascular events in people who have overweight or obesity. It does not cover Wegovy for weight loss.